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Abstract
Bacground/Aim. Chronic heart failure (CHF) is highly
prevalent and constitutes an important public health prob-
lem around the world. In spite of a large number of phar-
macological agents that successfully decrease mortality in
CHF, the effects on exercise tolerance and quality of life are
modest. Renal dysfunction is extremely common in patients
with CHF and it is strongly related not only to increased
mortality and morbidity but to a significant decrease in ex-
ercise tolerance, as well. The aim of our study was to inves-
tigate the prevalence and influence of the renal dysfunction
on functional capacity in the elderly CHF patients. Meth-
ods. We included 127 patients aged over 65 years in a stable
phase of CHF. The diagnosis of heart failure was based on
the latest diagnostic principles of the European Society of
Cardiology. The estimated glomerular filtration rate (eGRF)
was determined by the abbreviated Modification of Diet in
Renal Disease (MDRD2) formula, and patients were catego-
rized using the Kidney Disease Outcomes Quality Initiative
(K/DOQI) classification system. Functional capacity was
determined by the 6 minute walking test (6MWT). Results.
Among 127 patients, 90 were men. The average age was
72.5  ±  4.99 years and left ventricular ejection fraction
(LVEF) was 40.22 ± 9.89%. The average duration of CHF
was 3.79 ± 4.84 years. Ninty three (73.2%) patients were in
New York Heart Association (NYHA) class II and 34
(26.8%) in NYHA class III. Normal renal function (eGFR
 90 mL/min) had 8.9% of participants, 57.8% had eGFR
between 60–89 mL/min (stage 2 or mild reduction in GFR
according to K/DOQI classification), 32.2% had eGFR
between 30–59 mL/min (stage 3 or moderate reduction in
GFR) and 1.1% had eGFR between 15–29 mL/min (stage 4
or severe reduction in GFR). We found statistically signifi-
cant correlation between eGFR and 6 minute walking dis-
tance  (6MWD)  (r = 0.390,  p < 0.001),  LVEF  (r = 0.268,
p < 0.05), NYHA class (Ʊ = -0.269, p < 0.05) and age (r = -
0.214,  p  <  0.05). In multiple regression analysis only pa-
tients’ age was a predictor of decreased 6MWD < 300 m
(OR = 0.8736,  CI = 0.7804 - 0.9781,  p < 0.05).  Conclu-
sion.  Renal dysfunction is highly prevalent in the elderly
CHF patients. It is associated with decreased functional ca-
pacity and therefore with poor prognosis. This study cor-
roborates the use of eGFR not only as a powerful predictor
of mortality in CHF, but also as an indicator of the func-
tional capacity of cardiopulmonary system. However, clini-
cians underestimate a serial measurement of eGFR while it
should be the part of a routine evaluation performed in
every patient with CHF, particularly in the elderly popula-
tion.
Key words:
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Apstrakt
Uvod/Cilj. Srÿana insuficijencija (SI) je znaÿajan zdravs-
tveni problem koji ima epidemijske razmere. U terapiji SI
koriste se mnogobrojni lekovi koji utiÿu na smanjenje mor-
taliteta. MeĀutim, oni ne popravljaju znaÿajno funkcionalni
kapacitet i kvalitet života. Bubrežna disfunkcija, ÿesto pri-
sutna kod bolesnika sa SI, znaÿajno je udružena sa poveýa-
nim morbiditetom i mortalitetom, ali i sa smanjenim funk-
cionalnim kapacitetom. Cilj istraživanja bio je da se utvrdi
uÿestalost bubrežne disfunkcije i njen uticaj na funkcionalni
kapacitet kod starijih bolesnika sa stabilnom SI. Metode. U
istraživanje je bilo ukljuÿeno 127 bolesnika, starijih od 65
godina u stabilnoj fazi SI. Funkcionalni kapacitet odreĀivan
je pomoýu 6-minutnog testa hodom, glomerularne filtracije
(GFR) pomoýu skraýene Modification of Diet in Renal Disease
(MDRD) formule. Rezultati. Od ukupno 127 bolesnika u
stabilnoj fazi SI (proseÿnog  trajanja  3,79 ± 4,84  godina),
funkcionalne New York Heart Association (NYHA) klase II ili
III, 90 je bilo muškog pola. Njihova proseÿna starost izno-
sila je 72,5 ± 4,99 godina, a proseÿna ejekciona frakcija (EF)
40,2  ±  9,9%. Normalnu bubrežnu funkciju imalo je 8,9%Volumen 69, Broj 10 VOJNOSANITETSKI PREGLED Strana 841
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ispitanika, 57,8% bolesnika imalo je lako smanjenu GFR
[stadijum 2 prema Kidney Disease Outcomes Quality Initiative
(K/DOQI klasifikaciji), 32,2% imalo je umereno redukova-
nu GFR (stadijum 3) dok je 1,1% bolesnika imalo teško re-
dukovanu GFR (stadijum 4)]. NaĀena je znaÿajna korelacija
izmeĀu GFR i rastojanja preĀenog tokom 6-minutnog testa
hodom (r  =  0,390, p < 0,01),  EF  (r = 0,268,  p < 0,05),
NYHA klase (Ʊ = -0,269, p < 0,05) i životnog doba (r = -
0,214,  p  < 0,05). Jedini prognostiÿki pokazatelj rastojanja
preĀenog tokom 6-minutnog testa hodom ispod 300 m bila
je  starost  bolesnika  (OR = 0,8736,  CI = 0,7804  –  0,9781,
p < 0,05). Zakljuÿak. Najveýi broj ispitanika imao je bubre-
žnu disfunkciju koja je bila udružena sa smanjenim funkcio-
nalnim kapacitetom koji je u SI udružen sa lošom progno-
zom. Serijsko odreĀivanje GFR trebalo bi da bude rutinski
deo kliniÿkog pregleda svih bolesnika sa SI, posebno starijih.
Kljuÿne reÿi:
srce, insuficijencija; stare osobe; bubreg,
insuficijencija; glomerulska filtracija; kvalitet života.
Introduction
Chronic heart failure (CHF) is a disorder associated
with high mortality and persistent and prolonged hospitali-
zations, and affects over 10 million people in the countries
represented by the European Society of Cardiology. The pre-
valence of CHF increases markedly with age when the tre-
atment is often complicated by the presence of multiple co-
morbidities 
1. A significant portion, up to 39% of patients
with CHF, also has renal insufficiency, and the prevalence
increases with the age. Renal insufficiency is directly
associated with morbidity and mortality independent on
established risk factors such as New York Heart Association
(NYHA) class and left ventricle ejection fraction (LVEF) 
2, 3.
Chronic heart failure is now seen not only as a cardiac disor-
der but rather a cardiorenal and neurohumoral syndrome
which affects quality of life more profoundly than many ot-
her chronic diseases 
4, 5.
Survival in heart failure is closely related to functional
capacity and some studies suggest that quality of life is a
predictor of CHF course 
6, 7. Patients' functional status and
ultimately quality of life are impaired because the heart is
unable to meet the demands of skeletal musculature, and
symptoms manifest as signs of fatigue and dyspnea even in
patients with guideline-based optimized therapy. Abnormali-
ties in central hemodynamic function are not sufficient to
fully explain exercise intolerance in CHF because indices of
resting ventricular function such as LVEF are poorly corre-
lated with peak exercise capacity 
1, 8, 9.
However, not only heart failure, but advanced age and
renal dysfunction both closely related, have influence on
functional capacity 
10. The HF-ACTION trial showed that
reduced renal filtration is associated with impaired
cardiorespiratory fitness and a clustering of high-risk featu-
res in systolic heart failure patients which portend a more
complicated course and higher all-cause mortality 
11.
The ‘gold standard’ method for the assessment of func-
tional capacity is the cardiopulmonary exercise test (CPET).
However, CPET equipment is expensive and cumbersome,
and availability of trained staff is limited. A simple, self-
paced, and submaximal alternative is the 6 minute walk test
(6MWT) 
12. It is commonly used, and is both reproducible
and cheap to administer 
1.
The aim of our study was to assess the prevalence of
renal dysfunction and its influence on functional capacity in
elderly patients with stable CHF.
Methods
In our study we included 127 consecutive patients aged
over 65 years in a stable phase of CHF (2 weeks without
worsening of cardiovascular symptoms and without changes in
medical treatment or need for intravenous inotropic support)
who were recruited during the scheduled visit to the cardiolo-
gist. The diagnosis of heart failure was based on the latest dia-
gnostic principles of the European Society of Cardiology
(ESC) 
13. We enrolled patients with systolic (LVEF  45%)
and diastolic heart failure with NYHA function class II and III
with at least of one episode of acute cardiac decompensation.
Echocardiography measurements were performed on the Vivid
4, GE ultrasound system and LVEF was measured according
to the Simpson’s biplane method. Serum creatinine concentra-
tion was measured by the Jaffé method (alkaline picrate reac-
tion) with laboratory referent values 53–115 μmol/L. It is of-
ten quoted as a barometer of renal impairment, but it is
actually a poor indicator of renal function. Therefore, estimati-
on of the glomerular filtration rate (eGFR) is preferred for the
accurate assessment of renal function 
4, 10. The eGFR was de-
termined by the abbreviated Modification of Diet in Renal Di-
sease (MDRD) formula and patients were categorized using
the Kidney Disease Outcomes Quality Initiative (K/DOQI)
classification system 
14. The abbreviated MDRD formula pro-
vides valid estimation of glomerular filtration rate (GFR) and
according to recent findings it is superior to the Cockcroft-
Gault formula 
4, 15–18. According to the World Health
Organization (WHO) anemia is defined as hemoglobin (Hb)
concentration < 13.0 g/dL in men and < 12.0 g/dL in women 
19.
The presence of chronic obstructive pulmonary disease
(COPD) was assessed according to the definition of Global
Initiative for COPD – ,,GOLD” criteria: spirometrically asses-
sed ratio of a post-dilatory forced expiratory volume in the
first second divided by forced vital capacity (FEV1/FVC), the
so-called Tiffno index, less than 70% 
20. The functional
capacity was determined by the 6MWT. 6MWT was perfor-
med on flat floor, being 25 meters on straight line. The patients
were instructed to walk at their own pace while attempting to
cover as much ground as possible in 6 minutes. After 6 minu-
tes the distance walked was measured to the nearest meter.
The study was performed in Clinic for Cardiovascular Disease,
Clinical Center Niš. The study complied with the Declaration
of Helsinki. The Medical Ethical Committee of the Faculty of
Medicine, University of Niš, Niš, Serbia, approved the study
protocol. All participants submitted written informed consent.Strana 842 VOJNOSANITETSKI PREGLED Volumen 69, Broj 10
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Data are presented as mean r standard deviation (SD)
for continuous measures and as a proportion for categorical
variables. We used Pearson’s correlation coefficient (r) for
variables with normal distribution and Spearman’s rho cor-
relation coefficient (ȡ) for ordinal variables. Multiple regres-
sion analysis was used to determine predictors of reduced
6MWD and therefore, decreased functional capacity. All the
values of p were two-tailed and statistical significance was
established as p <  0.05. Statistical analysis was completed
using the SPSS software, version 17.0 for Windows.
Results
Among 127 patients, 90 (70.9%) were men. The baseline
patients’ characteristics are presented in Table 1. The average
age was 72.5 ± 4.99 years and LVEF was 40.22 ± 9.89%. The
average duration of CHF was 3.79 ± 4.84 years. Ninty three
(73.2%) patients were in NYHA class II and 34 (26.8%) in
NYHA class III. Only 17 (13.38%) patients had diastolic heart
failure (heart failure with preserved LVEF). Comorbidities and
previous medical procedures are presented in Table 2. The
etiology of heart failure is presented in Table 3. Twenty four
(18.9%) patients had anemia (the lowest value of hemoglobin
was 98 g/L) and 17 (13.38%) patients had COPD (the average
value of Tiffno index was 0.61). They were on stable medical
therapy during at least 2 weeks before inclusion in the study
(Table 4). Only 8.9% of the participants had eGFR  90
mL/min, 57.8% had eGFR between 60–89 mL/min (stage 2 or
mild reduction in GFR according to K/DOQI classification),
32.2% had eGFR between 30–59 mL/min (stage 3 or moderate
reduction in GFR) and 1.1% had eGFR between 15–29
mL/min (stage 4 or severe reduction in GFR) (Figure 1). Figu-
re 2 shows a scattered diagram with creatinin values grouped
in the adequate K/DOQI class. We correlated all the relevant
factors with the 6MWD and eGFR including LVEF, NYHA
class, age, gender, body mass index (BMI), heart rate (HR),
Table 3
Etiology of heart failure in the patients included in the
study
Etiology of CHF n (%) of patients
Ischemic heart disease 86 (67.6)
Arterial hypertension 30 (23.8)
Dilated cardiomyopathy 9 (7.4)
Valvular disease 2 (1.2)
Table 4
Cardiovascular medical treatment of the patients included
in the study
Medication n (%) of patients
ACE inhibitors 107 (84.5)
Beta blockers 127 (100)
Antiplatelet agents 105 (82.5)
Anticoagulants (vitamin K antagonist) 41 (32)
Digoxin 33 (25.8)
Diuretics 90 (71.1)
Spironolacton 60 (47.4)
Nitrates 63 (49.5)
Calcium antagonists 26 (20.6)
Statins 43 (34)
Amiodaron 14 (11.3)
Table 1
The baseline characteristics of the patients included in the study
Characteristics Mean ±  SD Min– Max
Age (years) 72.5 ± 4.996 63–86
Duration of CHF (years) 3.79 ± 4.836 0–11
LVEF (%) 40.22 ± 9.887 20–75
6MWD (m) 307.31 ± 100.055 60–513
Serum creatinine (μmol/L) 102.26 ± 31.820 66–281
eGFR (mL/min) 66.17 ± 18.451 15–109
Haemoglobin (g/L) 137.41 ± 14.948 98–172
BMI (kg/m
2) 26.55 ± 3.720 19–38
HR (/min) 72.77 ± 12.190 53–129
FEV1/VC (Tiffno index) 0.74 ± 0.094 0.43–0.96
CHF – chronic heart failure, LVEF – left ventricle ejection fraction,
6MWD – six minute walk distance, eGFR – estimated glomerular filtration rate, BMI – body mass
index, HR – heart rate
Table 2
Comorbidities and previous medical procedures in patients included in the study
Comorbidities and previous medical procedures n (%) of patients
Diabetes mellitus 38 (30.1)
Arterial hypertension 92 (72.6)
Dyslipidemia
COPD
54 (42.5)
17 (13.38)
Coronary artery disease 96 (75.7)
Previous myocardial infarction 76 (60.2)
Previous percutaneus coronary intervention 10 (8)
Previous coronary artery bypass surgery 18 (14.2)
COPD – chronic obstructive pulmonary diseaseVolumen 69, Broj 10 VOJNOSANITETSKI PREGLED Strana 843
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hemoglobin level, and the presence of COPD, systolic or dia-
stolic heart failure. A statistically significant correlation was
found between eGFR and 6MWD (r = 0.390, p < 0.01) (Figure
3), LVEF (r  =  0.268, p < 0.05),  NYHA  class  (ȡ =  -0.269,
p < 0.05), age (r = -0.214, p < 0.05) and female gender (ȡ = -
0.388, p < 0.01). However, there was no significant correlation
between 6MWD and creatinine (r = -1.75, p = 0.1; linear re-
gression, R
2 = 0.03, p = 0.1) (Figure 4). Six-minute walk dis-
tance correlated with NYHA class (ȡ = -0.231, p < 0.05),
age (r = -0.245, p < 0.01) and female gender (ȡ = - 0.446,
p < 00.01), as well. In multiple regression analysis (where
we included age, gender, the presence of COPD, anaemia,
eGFR, NYHA class, LVEF) only patients’ age was a pre-
dictor of decreased 6MWD < 300 m (OR = 0.8736, 95%,
CI = 0.7804 - 0.9781, p < 0.05). The probability of redu-
cing the 6MWD  < 300 m increased by 8.7% with every
year of age.
Discussion
Heart failure plays an important role in public health,
being one of the major complications of heart disease and
a leading cause of death in developed countries. The natu-
ral history of this illness constitutes impairment of functi-
onal capacity, physical performance, and ability to per-
form daily activities, finally becoming detrimental to the
quality of life 
9.
Concomitant and significant renal dysfunction is com-
mon in patients with heart failure 
21, 22. In the study of
Waldum et al., 
23 44.9% of the elderly outpatients with heart
failure had eGFR lower than 60 mL/min. Accordingly, in our
study 91.1% of patients had renal dysfunction and among
them 33.3% had moderate or severe renal dysfunction (eG-
FR < 60 mL/min). For adequate interpretation of epidemio-
logical studies it is essential to use the universal definitions
of renal dysfunction (GFR = 60–89 mL/min), renal impair-
ment and chronic kidney disease (GFR below 60 mL/min for
at least 3 months, among other criteria) 
14. As patients with
advanced heart failure are also likely to have an element of
renal dysfunction, it is of interest to know how
prognostically relevant this is. Renal impairment is often as-
sociated with CHF owing to renal hypoperfusion, diuretic
treatment, disease-modifying heart failure therapy (angioten-
sin-converting enzyme inhibitors, angiotensin II receptor
antagonists, aldosterone antagonists), as well as other con-
comitant medication and comorbidities 
4. Scardovi et al. 
24
showed that renal dysfunction in elderly CHF patients is a
main independent prognostic predictor across the spectrum
of ventricular impairment indices. Although the pathogenesis
of reduced GFR may differ between patients and even over
Fig. 1 – Percentage of patients with different stages of renal
dysfunction
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time within an individual, the result is the same: reduced
GFR is strongly related to increased mortality and morbidity
and impaired functional capacity in CHF.
In our study we found a significantly positive correlati-
on between eGFR and 6MWD, while NYHA class, female
gender and age inversely correlated with eGFR which is in
accordance with previous reports 
11, 25, 26. A positive correla-
tion was found between LVEF and eGFR. Although a greater
proportion of patients with low eGFR have a worse NYHA
class, no evidence of association between LVEF and eGFR
can be consistently demonstrated. Thus, patients with
systolic and diastolic CHF appear to have similar eGFR 
27.
Functional capacity provides a strong independent in-
sight into the prognosis of patients with heart failure. Infor-
mation on peak oxygen consumption (PvO2) during
cardiopulmonary exercise testing is used extensively to eva-
luate cardiovascular performance. Several studies have sup-
ported PvO2 as an independent prognostic index of survival
in patients with heart failure 
28.
The 6MWT has been proposed as a simple,
inexpensive, reproducible alternative to CPET. The test
showed a good reproducibility and a significant relation
between the distance walked during the test and the PvO2
and, respectively, survival has been demonstrated. The
6MWT reproduces the activity of daily life and this is
particularly relevant in elderly patients who usually develop
symptoms below their theoretical maximal exercise capacity 
6.
We determined a significant inverse correlation between
6MWD, NYHA class, age, female gender and renal
dysfunction (eGFR) which is in accordance with findings of
Ingle et al. 
12. However, hemoglobin concentration, BMI, re-
sting heart rate and the presence of COPD did not correlate
with 6MWD which is not in line with previous reports 
12, 29.
However, the lowest value of hemoglobin was 98 g/L, which
means that our patients had very mild anemia. Furthermore,
our patients with COPD had the average Tiffno index of 0.61
and therefore mild COPD, which could partially explain the
effect of those comorbidities on functional capacity. In our
study 6MWD significantly correlated with LVEF, and there
was no significant difference between patients with systolic
or diastolic heart failure, which is in line with published lite-
rature 
27, 30. It has been demonstrated that a walking distance
less than 300 m during the 6MWT is an independent predic-
tor of long-term mortality in patients with mild-to-moderate
heart failure 
28, 31. In our study, multiple regression analysis
showed that only patients’ age was a predictor of reduced
6MWD < 300 m. However, only 47.8% of our patients had
6MWD below 300 m, so more than 50% of our patients were
not included in this analysis. In the HF-ACTION study age
was the strongest predictor of PvO2 and a significant predic-
tor of exercise capacity. Age-dependent comorbidities, such
as renal dysfunction, do not explain changes in PvO2. Age-
related changes in cardiovascular physiology, potentially
magnified by the CHF, should be considered as a contributor
to the pathophysiology and a target for more effective
therapy in older patients with CHF 
32.
A number of biologically diverse chronic illnesses such
as renal failure, COPD and congestive heart failure result in
a significant decrease in exercise tolerance. In each of these
disease states, treatments aimed at the primary pathology ha-
ve provided powerful palliative effects. However, in general,
improvements in exercise tolerance following such interven-
tions are delayed and incomplete. This has led to an increa-
sing awareness that secondary treatment strategies, such as
prescribed exercise, designed to restore some level of
physical performance and quality of life can be beneficial 
33.
The American Heart Association has recently taken the posi-
tion that exercise rehabilitation has an important place in the
treatment of heart failure 
34. The potential mechanisms by
which CHF and renal dysfunction may negatively impact
skeletal muscle are complex, resulting from alterations in
muscle perfusion, substrate delivery, and catabolic state me-
diated by various factors such as metabolic acidosis, cortico-
steroids, proinflammatory cytokines, and decreased physical
activity, among others. In summary, numerous disorders
promote skeletal myopathy developement, impaired exercise
tolerance, and hence a sedentary lifestyle in CHF patients.
Reduction in physical activity, in turn, leads to further decli-
ne in muscle mass, progressive disability, and various other
untoward consequences. Regular exercise regimens can in-
terrupt this vicious cycle and improve physical condition.
Thus the inclusion of exercise as a standard component of
care appears to be warranted in the overall management of
these patients 
33, 35.Nevertheless, pharmacological manage-
ment, focused on kidney protection to prevent or slow pro-
gression of renal impairment, may improve outcome in
elderly HF patients 
24.
Conclusion
Renal dysfunction is highly prevalent in elderly CHF
patients. It is associated with decreased functional capacity
and, therefore, poor prognosis. This study corroborates the
use of eGFR not only as a powerful predictor of mortality in
CHF, but also as an indicator of the functional capacity of
cardiopulmonary system. Large, prospective studies remain
to be performated for understanding the etiology of reduced
eGFR in patients with CHF. Inclusion of patients with renal
insufficiency in heart failure studies and the published gui-
delines for medication, device, and interventional therapies
would likely improve therapeutic outcomes. This will lead to
novel therapeutic strategies not only in reducing mortality
but also in improving life quality in CHF. However, clinici-
ans underestimate serial measurement of eGFR while it sho-
uld be a part of routine evaluation initially performed in
every patient with CHF, particularly in elderly population.Volumen 69, Broj 10 VOJNOSANITETSKI PREGLED Strana 845
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